NVO

Novo Nordisk ADR

Feb 03 • 04:00PM ET

50.30

-8.63 -14.64 %

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Today, 12:45 PMNovo Nordisk launches a new stock buyback program of up to 15 billion Danish kroner alongside its 2026 outlook update.

Peers: LLY MRK ABBV JNJ AMGN AZN-D PFE SNY BMY GSK

| Held by: PVAL PPH AVDE FTHI PID WCMI RVER OZEM AQEC SAMT

Scroll to Statements

Index	-	P/E	14.65	EPS (ttm)	3.43	Insider Own	0.00%	Shs Outstand	3.37B	Perf Week	-20.02%
Market Cap	169.44B	Forward P/E	14.74	EPS next Y	3.41	Insider Trans	-	Shs Float	3.37B	Perf Month	-3.99%
Enterprise Value	180.24B	PEG	3.08	EPS next Q	0.93	Inst Own	9.03%	Short Float	0.84%	Perf Quarter	1.70%
Income	15.29B	P/S	3.63	EPS this Y	17.19%	Inst Trans	-1.57%	Short Ratio	1.37	Perf Half Y	3.05%
Sales	46.69B	P/B	8.36	EPS next Y	-7.92%	ROA	21.83%	Short Interest	28.16M	Perf YTD	-1.14%
Book/sh	6.02	P/C	33.04	EPS next 5Y	4.79%	ROE	68.30%	52W High	93.80 -46.38%	Perf Year	-40.44%
Cash/sh	1.52	P/FCF	16.94	EPS past 3/5Y	25.78% 21.74%	ROIC	37.50%	52W Low	43.08 16.76%	Perf 3Y	-27.15%
Dividend Est.	1.80 (3.58%)	EV/EBITDA	7.82	Sales past 3/5Y	23.46% 18.15%	Gross Margin	81.93%	Volatility	5.35% 3.55%	Perf 5Y	43.78%
Dividend TTM	1.73 (3.43%)	EV/Sales	3.86	EPS Y/Y TTM	11.24%	Oper. Margin	42.41%	ATR (14)	2.54	Perf 10Y	82.28%
Dividend Ex-Date	Aug 18, 2025	Quick Ratio	0.57	Sales Y/Y TTM	18.71%	Profit Margin	32.76%	RSI (14)	35.02	Recom	2.35
Dividend Gr. 3/5Y	28.20% 21.81%	Current Ratio	0.78	EPS Q/Q	-21.84%	SMA20	-15.21%	Beta	0.67	Target Price	61.94
Payout	35.93%	Debt/Eq	0.60	Sales Q/Q	11.80%	SMA50	-5.53%	Rel Volume	3.37	Prev Close	58.93
Employees	76302	LT Debt/Eq	0.52	Earnings	Feb 04 BMO	SMA200	-14.42%	Avg Volume	20.53M	Price	50.30
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.41% -3.47%	Trades		Volume	69,260,608	Change	-14.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral
Jul-31-25	Downgrade	HSBC Securities	Buy → Hold	$57
Jul-30-25	Downgrade	Barclays	Overweight → Equal Weight
Apr-17-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$64
Mar-13-25	Upgrade	Kepler	Hold → Buy
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Jan-06-25	Upgrade	Bernstein	Underperform → Mkt Perform
May-30-24	Initiated	Goldman	Buy	$156
Apr-12-24	Initiated	BMO Capital Markets	Outperform	$163
Jan-23-24	Initiated	Morgan Stanley	Overweight	$120

Show Previous Ratings

Today 04:36PM	These Stocks Are Todays Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More (Barrons.com) -14.64%
04:07PM	Novo Crashes After Projecting 2026 Decline; Surprising With Day-Early Report (Investor's Business Daily)
04:06PM	Pfizer Dives; Why Lilly's Zepbound Still Looks Like The Weight-Loss Heavyweight (Investor's Business Daily)
04:02PM	Pfizer Stock Drops on Obesity-Drug Study Data (The Wall Street Journal)
04:01PM	'Trump Home' reports, Novo warning, USIran tension lifts oil prices (Yahoo Finance Video)
03:22PM	Loading…
03:22PM	Novo Nordisk Stock Sinks as Ozempic Maker Sees Sales Falling in 2026 (Barrons.com)
02:48PM	Obesity Drug Bets Get a Reality Checkbut Investors Shouldnt Panic (The Wall Street Journal)
02:33PM	Novo Warns Sales Will Drop Due to Tougher US Competition (Bloomberg)
01:56PM	Novo Nordisk Stock Falls As 2026 Outlook Signals Pricing Pressure, Slowing Sales (Benzinga)
01:43PM	Novo Nordisk's stock tumbles as drugmaker lays out case for declining sales in 2026 (MarketWatch)
01:17PM	Novo Nordisk Stock Dives On Forecast for 2026 Sales Drop (The Wall Street Journal)
01:07PM	Wegovy Maker Novo Nordisk Forecasts Steep Sales Drop in 2026 (The Wall Street Journal)
12:49PM	Novo Nordisk shares plunge amid lower 2026 sales outlook (Investing.com)
12:27PM	Novo Nordisk Crashes After Projecting A 2026 Sales, Profit Slowdown (Investor's Business Daily)
12:04PM	Novo Nordisk Posts Better-Than-Expected 2025 Sales. Stock Sinks. (Barrons.com)
12:00PM	Loading…
12:00PM	Novo Nordisk data shows CagriSema superior in Phase 3 trial, says UBS (TipRanks)
11:32AM	Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data (Zacks)
10:43AM	NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study (Zacks)
03:01AM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-02-26 07:29PM	Novo Nordisk A/S (NVO): A Bull Case Theory (Insider Monkey)
06:02PM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
03:18PM	Jim Cramer Believes Novo Nordisk "Is a Hold, Not a Buy" (Insider Monkey)
02:12PM	Novo Nordisk's Next-Gen Combination Drug Beats Semaglutide in Weight Loss and Blood Sugar Control (Benzinga)
02:08PM	Is Novo Nordisk Stock a Bargain Right Now? (Motley Fool)
01:26PM	Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year (Benzinga)
11:00AM	AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC (Zacks)
10:46AM	McDonald's, Novo Nordisk, Humana: Top Analyst Calls (Yahoo Finance Video)
10:25AM	What's in Store for These 5 Pharma Bigwigs This Earnings Season? (Zacks)
09:17AM	Obesity market sales potential tightens as Novo and Lilly enter new era (Reuters Videos)
08:37AM	Beat the Market the Zacks Way: Five Below, Novo Nordisk, Ekso in Focus (Zacks)
08:29AM	Loading…
08:29AM	Palantir, AMD, Amazon and More Stocks with Earnings This Week (Benzinga)
07:15AM	Should Investors Buy, Sell or Hold Lilly Stock Ahead of Q4 Earnings? (Zacks)
06:07AM	Analysis-Obesity market sales potential tightens as Novo and Lilly enter new era (Reuters)
02:13AM	Jobs Report, Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-01-26 01:00PM	Commodity Volatility, Earnings and Other Key Things to Watch (Barchart)
07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-31-26 12:35PM	BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures (Insider Monkey)
12:30PM	Starbucks CEO Brian Niccol says rise of GLP-1s is behind company's protein push (Yahoo Finance)
07:05AM	Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? (Motley Fool)
12:24AM	Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill (Benzinga)
Jan-30-26 06:44PM	Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? (Motley Fool)
04:57PM	Jobs Report, More Tech Earnings: What to Watch Next Week (The Wall Street Journal)
01:59PM	Novo Jumps Ahead as Wegovy Pill Takes Off (GuruFocus.com)
12:57PM	Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases (Benzinga)
11:11AM	lkj lkj lkj lkj lkj lkj (Test Provider for Finance)
10:57AM	Novo Nordisk Shares Jump 14% as Wegovy Pill Launch Lifts Sentiment (GuruFocus.com)
10:08AM	Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic (Benzinga)
10:06AM	Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? (Zacks)
09:55AM	Novo's Wegovy pill surpasses 26,000 prescriptions in second full week (Reuters Videos)
08:47AM	Viking Therapeutics to Report Q4 Earnings: Here's What to Know (Zacks)
07:58AM	Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings? (Zacks)
03:00AM	How Big Pharma is navigating a $300 billion patent cliff (Pharma Voice)
02:53AM	Novo Obesity Pill Spurs Rally After Stocks Worst Ever Year (Bloomberg)
02:51AM	AstraZeneca Strikes Multibillion-Dollar Obesity Deal With Chinas CSPC (The Wall Street Journal)
Jan-29-26 04:22PM	How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity (Investor's Business Daily)
12:36PM	Novo Nordisk Faces Class Action Over Victoza Generic Delay (GuruFocus.com)
09:48AM	RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER (Zacks)
06:58AM	Novo Nordisk Doubles U.S. Ad Spend on Wegovy, Ozempic (GuruFocus.com)
Jan-28-26 04:20PM	2 Beaten-Down Growth Stocks Ready to Bounce Back (Motley Fool)
03:01PM	Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25% (GuruFocus.com)
12:20PM	Layoffs are piling up, heightening worker anxiety. Here are some of the biggest job cuts recently (Associated Press Finance)
09:09AM	Roche Reports Upbeat Efficacy Data From Phase II Obesity Study (Zacks)
06:31AM	India Obesity Drug Fight Is About to Intensify (GuruFocus.com)
06:06AM	Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows (Reuters)
01:50AM	1 Biotech Stock Set to Rebound in 2026 (Motley Fool)
Jan-27-26 05:45PM	Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors (Zacks)
02:35PM	Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss (GuruFocus.com)
01:00PM	1 Pharmaceutical Stock Set to Rebound in 2026 (Motley Fool)
12:32PM	Another Government Shutdown Looms: These 10 Stocks Suffered Last Time (Benzinga)
11:16AM	Citi initiates coverage of European pharma stocks; AstraZeneca best in class (Investing.com)
10:37AM	2 Pharmaceutical Stocks Set to Rebound in 2026 (Motley Fool)
09:41AM	Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet? (Zacks)
09:27AM	Where Will Eli Lilly Be in 10 Years? (Motley Fool)
06:31AM	Roche, trailing in obesity, showcases new data for GLP-1 shot (BioPharma Dive)
06:21AM	Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight (Benzinga)
04:10AM	Roche Obesity Shot Helps Patients Lose Weight in Midstage Trial (The Wall Street Journal)
Jan-26-26 09:20AM	Prediction: This Healthcare Stock Could Soar by 40% in 2026 (Motley Fool)
09:15AM	How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results? (Zacks)
Jan-24-26 08:35PM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
03:25PM	Should You Dump Eli Lilly's Shares After This Setback? (Motley Fool)
Jan-23-26 04:04PM	Oral Wegovy Is Off To An Astronomical Launch. Will It Save Novo Nordisk Stock? (Investor's Business Daily)
12:58PM	Novo Nordisk Wegovy Pill Sees Strong Launch (GuruFocus.com)
12:06PM	Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues (Investor's Business Daily)
10:36AM	VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion (24/7 Wall St.)
09:18AM	Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It (Benzinga)
09:12AM	Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record (Benzinga)
09:00AM	Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? (Zacks)
05:30AM	Premarket movers: Intel tumbles, Capital One slips, Spotify gains (MarketWatch)
05:27AM	Novo climbs higher on strong Wegovy pill launch; Terns tweaks leukemia drug deal (BioPharma Dive)
04:28AM	It's a hit: Wegovy weight-loss drug pill prescriptions surge (MarketWatch)
Jan-22-26 09:10AM	Jim Cramer on Novo Nordisk: "I Think They're Making a Turn Here" (Insider Monkey)
Jan-21-26 05:45PM	Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
04:39PM	Why Eli Lilly Is The IBD Stock Of The Day Again As Its Novo Nordisk Rivalry Deepens (Investor's Business Daily)
03:32PM	Markets Rally As Trump Drops Greenland's Tariff Threat: These 10 Stocks Are Soaring (Benzinga)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
10:00AM	The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1? (Barchart)
06:34AM	Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies (Pharmaceutical Business Review)
Jan-20-26 03:05PM	Is Oral Wegovy a Game Changer for Novo Nordisk? (Motley Fool)
01:21PM	Novo Nordisk Expands Diabetes Partnership With Aspect Biosystems (GuruFocus.com)
08:08AM	Which Pharma Stock Stands Taller Right Now: LLY or PFE? (Zacks)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience